BACKGROUND Anticoagulation is essential for the treatment and prevention of
thromboembolic events. Current guidelines recommend direct oral anticoagulants (DOACs) …

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran)
and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical …

The indications of direct oral anticoagulants (DOACs) have expanded over the past 15
years. DOACs are effective and safe oral anticoagulants associated with lower bleeding …

Direct oral anticoagulants (DOACs) have at least noninferior efficacy compared with other
oral anticoagulants and have ancillary benefits, including overall better safety profiles, lack …

Non-vitamin K oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban,
and edoxaban, are increasingly used for thromboembolism prevention. Contrary to older …

New oral anticoagulants (NOACs) have been developed in recent years and are
increasingly used in clinical practice. Dabigatran is a direct thrombin (factor II) inhibitor while …

Direct oral anticoagulants (DOACs) are a relatively recent addition to the oral anticoagulant
armamentarium, and provide an alternative to the use of vitamin K antagonists such as …

NOACs like dabigatran etexilate, rivaroxaban, apixaban and edoxaban are effective
alternatives to warfarin in primary and secondary prophylaxis of thromboembolic conditions …

Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short-and
long-term anticoagulation, mainly due to their ease of use and the lack of monitoring …

Most currently used DOACs are factor Xa inhibitors and should be stopped for 24–48 h for
elective surgical procedures in patients at risk for bleeding and potentially longer for …